Nupathe Awaits FDA Decision for Migraine Patch

NuPathe may gain approval for its first commercial product Zecuity, a transdermal migraine patch, this week. The company received a Prescription Drug User Fee Act (PDUFA) date of Jan.17 from the FDA.

Click here to continue reading.

Bloomberg BRIEF Newsletters